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Inhibition of Contact Sensitivity by
Farnesylthiosalicylic Acid-Amide, a Potential
Rap1 Inhibitor
Adam Mor1,2, Roni Haklai2, Ofer Ben-Moshe2, Yoseph A. Mekori3,4 and Yoel Kloog2,4
We hypothesized that Ras proximate 1 (Rap1) functions as an additional target for farnesylthiosalicylic acid (FTS)
or its derivatives, and that the inhibition of Rap1 in lymphocytes by these agents may represent a method for
treating inflammatory disorders. Indeed, we found that FTS-amide (FTS-A) was able to inhibit the elicitation
phase of delayed cutaneous hypersensitivity in vivo. This effect was associated with the inhibition of Rap1 more
than with the inhibition of Harvey rat sarcoma viral oncogene (Ras). Moreover, FTS-A inhibited Rap1 and contact
sensitivity far better than FTS. We suggest that FTS-A may serve as a possible therapeutic tool in contact
sensitivity in particular and T-cell-mediated inflammation in general.
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INTRODUCTION
Lymphocytes are the major cellular component of the
adaptive immune response. Normal function of lymphocytes
depends on several small guanosine nucleotide-binding
proteins (also known as small G proteins). This superfamily
of proteins consists of over 50 members that cycle between
an inactive guanosine diphosphate bound state and an active
guanosine triphosphate (GTP) bound state. These proteins are
involved in a variety of signal transduction pathways that
regulate lymphocyte growth, trafficking, migration, and
apoptosis (Scheele et al., 2007). Among the most studied
are Harvey rat sarcoma viral oncogene (Ras), Rheb, Rho, Rac,
and Ras proximate 1 (Rap1; Scheele et al., 2007).
Both Rap1 and Ras are highly expressed in T lymphocytes.
Rap1 was first identified as an antagonist for Ras. Active Rap1
can bind but not activate Raf-1, and thereby may sequester
Raf-1 from the Ras/extracellular signal-regulated kinase
pathway (Mor et al., 2007a). Another pathway through
which Rap1 can antagonize Ras function in T cells is the
suppression of Ras-dependent reactive oxygen species.
Finally, p38 activation by IL-1, characterized as Ras
dependent, is antagonized by Rap1. In contrast, in other
pathways, Rap1 and Ras synergize. For example, TCR
stimulation results in activation of both Rap1 and Ras.
These findings are an example of the Rap1–Ras complexity
and the concept of Ras antagonism by Rap1 remains
controversial (Dillon et al., 2005; Mor et al., 2007a).
Growth control, protein trafficking, and polarity are some
of the processes in which Rap1 has been implicated. The
best-characterized and most prominent function of Rap1 is to
promote lymphocyte function-associated antigen-1-mediated
adhesion. Lymphocyte function-associated antigen-1 activa-
tion by Rap1 is a critical step for lymphocytes homing to
peripheral lymph nodes and migrating into inflamed tissues
(Dillon et al., 2005). Inhibition of Rap1 abrogates lymphocyte
function-associated antigen-1-mediated adhesion to antigen-
presenting cells and IL-2 production (Mor et al., 2007a). In
some patients with leukocyte adhesion deficiency III, a defect
in Rap1 GTP loading is responsible for the profound defect
in lymphocyte adhesiveness (Abram and Lowell, 2009; Mor
et al., 2009), which highlighting the critical role of Rap1 in
host defense.
Small G protein-dependent signaling requires both GTP
binding and inner cell membrane anchorage. These proteins
are attached to lipid membranes through a lipid moiety, such
as farnesyl, prenyl, or gernylgernyl. Approaches to inhibit Ras
include the use of Ras inhibitors farnesylation (farnesyl-
transferase inhibitors; Zhu et al., 2003) and the use of S-trans-
farnesylthiosalicylic acid (FTS), a synthetic compound that
resembles the carboxyl-terminal farnesylcysteine of Ras
(Pando et al., 2010). Cells readily take up FTS, and once
inside the cell, it specifically disrupts the association of active
forms of Ras with the inner surface of the cell membranes
(Goldberg et al., 2008). FTS reduced the amount of Ras in a
dose-dependent manner (Weisz et al., 1999; George et al.,
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2004). The selectivity of FTS to active Ras may explain the
relatively non-toxic nature of this compound. When FTS
was given to patients with malignancies in clinical trials,
adverse effects were uncommon (http://clinicaltrials.gov). FTS
has been shown to have beneficial effects not only in animal
models of proliferative diseases but also in experimental
autoimmune neuritis (Kafri et al., 2005), MRL/lpr lupus prone
mice (Katzav et al., 2001), and myocarditis (Pando et al.,
2010).
Although FTS interferes with activated Ras membrane
anchorage, it can also affect directly or indirectly other small
G-binding proteins (Goldberg and Kloog, 2006). For exam-
ple, FTS shifts the balance between Rac1 and Rho activation
(Zundelevich et al., 2007). FTS is also an inhibitor of
isoprenylcysteine carboxyl methyltransferase (Marom et al.,
1995). A potential Ras inhibitor should prevent both
farnesylation and geranylgeranylation of Ras. FTS, with its
15-carbon farnesyl moiety, was found to inhibit both
farnesylation and geranylgeranylation of Ras (Elad et al.,
1999; Jansen et al., 1999). Farnesyltransferase inhibitors, on
the other hand, inhibit only Ras farnesylation, thus limiting its
potential clinical use as a therapeutic agent.
We hypothesized that Rap1 functions as an additional
target for FTS or its derivatives, and that the inhibition of
Rap1 in lymphocytes may represent a, previously unreported,
method for treating inflammatory skin disorders. Surprisingly,
we found that FTS was able to inhibit the elicitation phase
of delayed cutaneous hypersensitivity in vivo. This effect was
associated with inhibition of Rap1 more than with the
inhibition of Ras. Moreover, FTS-amide (FTS-A) inhibited
Rap1 and contact sensitivity far better than FTS.
Contact sensitivity is the immunological response to an
allergen, which may lead to allergic contact dermatitis. The
underlying pathophysiology of this disorder is exposure to
an antigen that activates T cells, thereby promoting the
release of inflammatory mediators, resulting in a delayed
phase cutaneous reaction. The established pharmacological
agents available to treat this disorder are limited. Options
include glucocorticosteroids and antihistamines. It is of great
value to develop a new therapeutic tool in contact sensitivity
for several reasons. First, current agents lack suitable
effectiveness. Second, considerable side effects of the existing
drugs often limit treatment, especially in long-term or
recurrent management. In addition, a, to our knowledge,
previously unreported agent may be potentially administered
before an exposure known to trigger contact sensitivity in
order to prevent the inflammatory response. To develop a
more effective management, research should identify new
pathways for intervention. Cutaneous exposure to antigens
triggers a diversity of intracellular signaling cascades—many
of which are Rap1 dependent. Thus, FTS-A might be of great
significance in serving as a therapeutic agent in contact
sensitivity, mediated through the inhibition of Rap1.
RESULTS
FTS derivatives inhibit Rap1 in Jurkat T cells
We inquired whether FTS and its derivatives are able to inhibit
GTP loading of Rap1. Quiescent Jurkat T cells were treated
overnight with FTS, FTS-A, and FTS-methoxymethylester
(MOM), each at a concentration of 50mM. Cells were collected,
and the quantity of GTP-Rap1 was determined by pull-down
assay. Compared with the untreated cells (control), the amount
of GTP-Rap1 decreased in all conditions (Figure 1a). However,
both FTS-A and FTS-MOM were superior to FTS in their ability
to inhibit Rap1 activation (Figure 1a).
Rap1 is activated in T cells as a result of crosslinking
the antigen receptor. We wanted to study the effect of FTS,
and its derivatives, on Rap1 activation in stimulated T cells.
Cells were treated with FTS, and its derivatives overnight,
and subsequently stimulated with anti-CD3 antibodies for
10minutes. As shown in Figure 1b, all derivatives were able
to inhibit Rap1 activation in stimulated T cells. FTS lowered
the amount of GTP-Rap1 by 32%, whereas FTS-A and FTS-
MOM lowered it by 60 and 53%, respectively (Figure 1c).
Thus, FTS and its derivatives are able to inhibit Rap1
activation in T cells stimulated through the antigen receptor.
However, it seems that FTS-A and FTS-MOM were more
potent Rap1 inhibitors compared with FTS.
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Figure 1. FTS derivatives inhibit Rap1 in Jurkat T cells. Jurkat T cells
were treated overnight with FTS, FTS-A, and FTS-MOM (50mM). GTP-loaded
Rap1 was determined by pull-down assay (a). Jurkat T cells were treated
with FTS and its derivatives overnight (50 mM), and subsequently stimulated
with anti-CD3 antibodies for 10minutes. GTP-Rap1 was determined by
pull-down assay (b). Quantification of the same experiments (n¼ 4,
mean±s.e.m) is shown in c. *Pp0.05; relative to control. FTS, farnesyl-
thiosalicylic acid; FTS-A, FTS-amide; FTS-MOM, FTS-methoxymethylester;
GTP, guanosine triphosphate; Rap1, ras proximate 1.
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FTS derivatives inhibit T-cell adhesion
As Rap1 is critical for T-cell adhesion, we tested the ability
of FTS and its derivatives to inhibit adhesion of T cells to
ICAM-1-coated plates. T cells were treated overnight with FTS
or its derivatives. Cells were plated on ICAM-1-coated wells
for 20minutes followed by serial washings. A plate reader
was used to evaluate the percentage of cells that remained in
the wells. Although 40% of stimulated T cells attached to
the ICAM-1-coated wells, this number dropped by half in
wells that were treated with the derivatives (Figure 2). No
statistically significant difference could be found among
the three agents. Thus, FTS, and its derivatives, inhibit both
Rap1 GTP loading and Rap1-dependent T-cell adhesion.
FTS-A inhibition of Rap1 is dose dependent
Out of the three agents (FTS, FTS-A, and FTS-MOM), we
chose to focus on FTS-A mainly because of its superiority in
terms of Rap1 inhibition (Figure 1c). First, we treated T cells
with various concentration of FTS-A for 72 hours. As shown in
Figure 3a, with higher dose, the number of viable cells
decreased, as assessed by trypan blue exclusion. Notably,
with higher dose of FTS-A, the amount of GTP-Rap1 among
the viable cells (dead cells were excluded based on specific
density centrifugation) further diminished, indicating a
dose–response relationship (Figure 3b). We limited the
concentration of FTS-A in this experiment to 50 mmol l1, as
further inhibition was accompanied by the loss of cell
viability. Interestingly, only high concentration of FTS-A
inhibited adhesion to ICAM-1-coated plates (Figure 3c).
FTS-A inhibits Rap1 activation at the plasma membrane
We have previously reported that only the pool of Rap1 at the
plasma membrane becomes GTP bound on lymphocyte
activation (Mor et al., 2009). We wanted to study whether
Rap1 inhibition by FTS-A is indeed restricted to that
compartment. Jurkat T cells, expressing green fluorescent
protein (GFP)-tagged Rap1, were subjected to various agents
(Figure 4a), whereas the localization of Rap1 was recorded by
confocal microscopy. As previously reported, knocking down
phospholipase D 1 (PLD1) resulted in inhibition of Rap1 and
its association with the plasma membrane (Figure 4a). FTS-A
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Figure 2. FTS derivatives inhibit T-cell adhesion. Jurkat T cells were treated
overnight with FTS or its derivatives (50mM) as indicated. Cells were plated on
ICAM-1-coated wells for 20minutes followed by serial washings. A plate
reader was used to evaluate the percentage of cells that remained in the wells
(n¼4, mean±s.e.m). *Pp0.05; relative to control. FTS, farnesylthiosalicylic
acid; FTS-A, FTS-amide; FTS-MOM, FTS-methoxymethylester; NT, not
treated.
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Figure 3. FTS-A inhibition of Rap1 is dose dependent. Jurkat T cells were
treated with various concentration of FTS-A (as indicated) for 72 hours.
Viable cells were assessed by trypan blue exclusion (n¼ 3, mean±s.e.m) (a).
Jurkat T cells were treated with different concentrations of FTS-A (as
indicated) and the amount of GTP-Rap1 was evaluated by pull-down assay
(n¼3, mean±s.e.m) (b). T cells were treated with different concentrations of
FTS-A and adhesion to ICAM-1-coated wells was studied as described
earlier (n¼4, mean±s.e.m; c). *Pp0.05; relative to control. FTS,
farnesylthiosalicylic acid; FTS-A, FTS-amide; NT, not treated;
Rap1, ras proximate 1.
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treatment for up to 72 hours did not change the localization
of overexpressed Rap1 (Figure 4a).
Rap1, similar to K-Ras, is associated with the plasma
membrane through farnesylation that functions in conjunc-
tion with an adjacent polybasic sequence. Bryostatin-1,
a protein kinase C agonist, induced a rapid translocation of
K-Ras from the plasma membrane to intracellular membranes
(Bivona et al., 2006). Nonetheless, we found that a combined
treatment with bryostatin-1 and FTS-A did not change the
localization of Rap-1 (Figure 4a). Thus, FTS-A does not
change the bulk localization of Rap1.
The effects of FTS are rather specific to the active
GTP-bound forms of Ras proteins (Marom et al., 1995). To
investigate the possible effect of FTS-A on localization of
the active Rap1, we took advantage of the probe for activated
Rap1, GFP-RBDRALGDS (Bivona and Philips, 2005). Consistent
with earlier reports (Bivona et al., 2004), when the cells were
stimulated through the antigen receptor, the probe trans-
located to the plasma membrane, suggesting that Rap1 is
activated at that compartment (Figure 4b). In cells that were
pretreated by FTS-A, the activation of Rap1 at the plasma
membrane was blocked (Figure 4b), although Rap1 remained
associated with the plasma membrane (Figure 4a). Thus, the
pool of Rap1, which is inhibited by FTS-A, is found at the
plasma membrane.
FTS-A inhibits contact sensitivity reaction in animal model
Next, the ability of FTS-A to inhibit Rap1-dependent T-cell
adhesion in vivo was investigated by using contact sensitivity
(Claman and Jaffee, 1983) as a model system. Animals were
treated orally with two different concentrations of FTS-A
(50 and 100mgkg1). Topical betamethasone (0.05%) served
as positive control. As shown in Figure 5a, high concentration
FTS-A was able to inhibit ear swelling. This effect was more
prominent after 48 hours (Figure 5a). When treatment was
introduced only during the challenge phase (days 5–6), ear
swelling was also attenuated. Treatment during the sensitiza-
tion phase (days 0–2) did not prevent ear swelling (Figure 5b),
suggesting that FTS-A primarily blocked lymphocyte recruit-
ment to the site of foreign antigen encounter. To characterize
the inflammatory response at the cellular level, mice were
treated as above, and at 48 hours latter, the epicutaneous
challenged ears were cut and analyzed. Heavy mono-
nuclear cell infiltrate characterizes the positive control group
(Figure 5c) in correlation with the macroscopic appearance of
the ear. Both FTS-A and topical betamethasone reduced the
cellular infiltrate (Figure 5c). There was no significant
difference between the ability of FTS-A or betamethasone to
reduce the infiltrate. The majority of these cells were
T lymphocytes (CD3 positive; Figure 5d). Few mast cells
and B cells were detected in all conditions (Figure 5d).
Quantification of the cellular infiltrate in this experiment
revealed a significantly reduced number of T cells in the
treatment group (Figure 5e). These cells expressed Rap1
(Figure 5d). Finally, we tested whether FTS-A could affect the
systemic inflammatory response triggered by exposure to
DNFB (2,4-Dinitro-l-fluorobenzene). Although not statistically
significant, serum levels of tumor necrosis factor (TNF)-a
were attenuated when treated with FTS-A (Figure 5f).
Rap1 inhibition by FTS-A is not associated with Ras inhibition
As FTS was shown to inhibit Ras, we inquired whether the
mechanism of Rap1 inhibition by FTS derivatives is indirect
and mediated by Ras inhibition. We compared the inhibitory
profile of FTS and its derivatives on both Ras GTP loading and
Rap1 GTP loading in Panc-1 cells (Figure 6a). As previously
reported, FTS-MOM was a weak Ras inhibitor, whereas FTS
was comparable with FTS-A. In contrast, FTS-MOM was by
far the stronger Rap1 inhibitor, whereas FTS was modest
(Figure 6a). Thus, the extent of Ras and Rap1 inhibition by
FTS and its derivatives is not identical.
Furthermore, when we knocked down N-Ras and K-Ras by
short hairpin RNA (shRNA) in Jurkat T cells, the inhibitory
effect of FTS-A on Rap1 was not interrupted, suggesting
again that Rap1 inhibition is probably not Ras dependent
(Figure 6b).
DISCUSSION
In this study, we demonstrated that, rather surprisingly, Rap1
activation is inhibited by FTS and its derivatives. We found
that FTS-A is by far a better inhibitor of Rap1 than FTS (Figure
6a and b), suggesting that the effect of FTS-A on contact
sensitivity (Figure 5a) is through the inhibition of Rap1. We
also showed that Rap1-mediated adhesion of lymphocytes
was blocked by FTS-A. As there is considerable cross-talk
between small G proteins, a major concern is whether
the inhibitory effect of FTS-A on Rap1 is indeed direct or
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Figure 4. FTS-A inhibits Rap1 activation at the plasma membrane.
Jurkat T cells, expressing GTP-tagged Rap1, were subjected to various
agents (as indicated) and the localization of Rap1 was recorded by
confocal microscopy (a). Jurkat T cells expressing the probe for activated
Rap1, GFP-RBDRALGDS were stimulated through the antigen receptor,
and the localization of the probe was recorded by confocal microscopy
with and without pretreatment with FTS-A at 50 mM (b). Bars¼ 5 mm (a, b).
FTS-A, farnesylthiosalicylic acid-amide; GFP, green fluorescent protein;
PLD-1, phospholipase-1; Rap1, ras proximate 1; shRNA, short
hairpin RNA.
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alternatively mediated through linkage to Ras. In this study,
we presented evidence that does not support such a Ras–Rap1
linkage. The effect of FTS-A on Rap1 activation was
unchanged when Ras was knocked down, suggesting that
Ras was not required for both Rap1 activation and for FTS-A-
mediated inhibition of Rap1 activation (Figure 6b). Similar
results were obtained in experiments with dominant-negative
Ras (data not shown). FTS-MOM was a strong Rap1 inhibitor
(Figure 6a), whereas it had only a minor inhibitory effect
on Ras (Figure 6b; Goldberg et al., 2009). These results
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demonstrate a distinct profile of inhibition for these two small
G-binding proteins: relatively high selectivity of FTS toward
Ras and of FTS-MOM toward Rap1. Although FTS-A inhibited
both Ras and Rap1, FTS-MOM was more selective toward
Rap1; we chose to use FTS-A for the contact sensitivity model
system. We did so because FTS-A showed the highest anti-
Rap1 activity. Rap1 is the key factor in the development of
delayed cutaneous hypersensitivity syndrome, and it is likely
that FTS-A affects mostly Rap1 under these circumstances.
Our results suggest that FTS-A is a potential new therapeutic
agent for delayed cutaneous hypersensitivity syndrome,
a common skin disorder with a median prevalence of
21% (Thyssen et al., 2007; Carlsen et al., 2008). To our
knowledge, this is previously unreported.
Our study is not free of weaknesses and limitations.
We can not be certain that our model for contact allergic
dermatitis in laboratory animals accurately represents
cutaneous immunology in humans, in whom the effect
on dendritic cells might be different (Bergstresser, 1989).
In addition, our therapeutic interventions were not able to
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Figure 6. Rap1 inhibition by FTS-A is not associated with Ras inhibition. Panc-1 cells were treated with different FTS derivatives (50 mM) and pull-down
assay for GTP loaded Rap1 and Ras were recorded (a). N-Ras and K-Ras were knocked down in Jurkat T cells (with shRNA) and the localization of
activated Rap1 was evaluated (b). Bars¼5 mm (b). FTS, farnesylthiosalicylic acid; FTS-A, FTS-amide; FTS-MOM, FTS-methoxymethylester; GFP, green
fluorescent protein; GTP, guanosine triphosphate; Rap1, ras proximate 1; shRNA, short hairpin RNA.
Figure 5. FTS-A inhibits contact sensitivity reaction in animal models. Animals were treated orally with two different concentrations of FTS-A (50 and
100mg kg1) or with daily topical application of betamethasone (0.05%) and ear swelling was evaluated after induction of contact sensitivity (a). Animals were
treated with FTS-A during the challenge phase (days 5–6) or during the sensitization phase (days 0–2), and ear swelling was studied (b). Macroscopic and
histological assessment of the ears of mice after treatments as indicated above; sections were stained with H&E and imaged at 10 and  20 magnification (c).
Immunohistochemical evaluations of tissue sections with anti-CD3, B220, Rap1, and toluidine blue were imaged at  40 magnification (d). Quantification of
the number of CD3-positive cells per high-power field views (e) were recorded. Mice were bled at 48 hours after challenge and serum level of TNF-a was
documented by ELISA (f). Results are shown as mean±s.e.m (n¼5–10 in each group). *Pp0.05; relative to control. Bars¼100 mm (c) and 50 mm (d). FTS-A,
farnesylthiosalicylic acid-amide; H&E, hematoxylin and eosin; Rap1, ras proximate 1; TNF-a, tumor necrosis factor.
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demonstrate a significant effect on serum TNF-a levels. Thus,
the cytokine levels should have been studied by tissue mRNA
quantification.
In a review of the current literature, several investi-
gators published observations that further disrupt the asso-
ciation between Ras and Rap1 (Mor et al., 2007a). Mst1 is a
kinase that is found downstream of both Ras and Rap1
(Mor et al., 2007a). In one study, cells treated with FTS did
not show any divergence in Mst1 activation, whereas Ras
was significantly inhibited (Pando et al., 2009). Others showed
that cellular adhesion is one of the Ras-independent Rap1
functions (Carey et al., 2000; Dillon et al., 2005; Mor et al.,
2009). Thus, it seems that the inhibitory effect of FTS on these
small G proteins is not interrelated (Pando et al., 2009).
Previous work was carried out in an effort to find new FTS
derivatives that might improve the anti-cancer effect of the
drug (Goldberg et al., 2009). It was shown that specific
modifications of the FTS carboxyl group by esterification
(e.g., FTS-MOM) or amidation (e.g., FTS-A) yielded com-
pounds with improved growth inhibition activity (Goldberg
et al., 2009) and with improved tissue penetration by its
increased lipophilicity (Goldberg et al., 2009). Of all
derivatives, FTS-A seems to be the most effective. FTS-A
exhibits good bioavailability after oral administration, has an
excellent safety profile, and may thus be considered for
clinical trials (Barkan et al., 2006; Haklai et al., 2008). In this
study, we showed that FTS-A was the most potent Rap1
inhibitor in T cells stimulated by the antigen receptor.
Interestingly, the FTS geranylgeranyl analog did not prove
to be a stronger Rap1 inhibitor (data not shown).
In this study, we showed that the development of contact
sensitivity reaction to DNFB in animal models was strongly
inhibited by FTS-A. Contact sensitivity to DNFB has been
extensively studied in mice. It requires both effective immune
sensitization following cutaneous exposure to chemical
haptens- and antigen-specific elicitation (Zimber et al.,
1982; Bryce et al., 2004). We showed that treatment with
FTS-A during the second exposure to the antigen was
sufficient to block ear swelling. It is, therefore, suggested
that the drug can block the recruitment of the primed T cells
to the inflamed area. Thus, we suggest that FTS-A might be a
promising candidate to treat patients with inflammatory
diseases, in which T-cell adhesion and recruitment has a
major role.
MATERIALS AND METHODS
General reagents
The 5-carboxyuorescein and Opti-MEMI were purchased from
Invitrogen Corporation/Molecular Probes (Carlsbad, CA). Bryosta-
tin-1 was provided by Sigma-Aldrich (St Louis, MO). FTS was
synthesized, as previously described (Haklai et al., 2008), and was
stored in chloroform, which was evaporated under a stream of
nitrogen immediately before use. FTS-MOM and FTS-A were
provided by the Concordia Pharmaceuticals (Fort Lauderdale, FL).
Antibodies and DNA constructs
Mouse anti-human CD3 (Ancell, Bayport, MN) was used for T-cell
activation.
Anti-Rap1antibody was purchased from BD Biosciences (San
Jose, CA). Monoclonal anti-Ras antibody (Ras10) was purchased
from Calbiochem (San Diego, CA). For immunohistochemistry,
tissue sections were stained with anti-B220 (BD Biosciences), anti-
CD3, and anti-Rap1 antibodies (Abcam, Cambridge, MA).
GFP-Rap1WT, pcDNA-Rap1WT, pcDNA-Rap1N17, GFP-RalGDSRBD,
shRNA-RFP/H1-PLD1, shRNA-scramble, shRNA-N-Ras, and shRNA-K-
Ras constructs were described and validated previously (Kafri et al.,
2005; Mor et al., 2007b, 2009).
Cell culture, transfection, and stimulation
Jurkat T cells were obtained from the American Type Culture
Collection (Manassas, VA). The cells were maintained in RPMI 1640
supplemented with 10% fetal calf serum, 2mM L-glutamine, and 1%
penicillin/streptomycin (Biological Industries, Kibutz Beit Haemek,
Israel). Panc-1 cells (American Type Culture Collection) were grown
in DMEM containing 10% fetal calf serum, 2mM L-glutamine, and
1% penicillin/streptomycin. The cells were incubated at 37 1C in a
humidied atmosphere of 95% air and 5% CO2. Transfection of
Jurkat cells was performed with DMRIE-C (Invitrogen Corporation/
Molecular Probes), and cells were examined at 24 to 48 hours later.
Jurkat T cells were serum starved at 37 1C for 2–6 hours, followed by
stimulation with 5mgml1 of mouse anti-human CD3.
Glutathione S-transferase pull-down assay
Detection of activated Ras and Rap1 was performed as described
previously (Mor et al., 2007b, 2009).
SDS-PAGE and immunoblotting
Samples were separated by SDS-PAGE using 10% polyacrylamide
gels and transferred to nitrocellulose filters. Blots were blocked
for 1 hours in TBST (10mM Tris-HCl (pH 8.0), 150mM NaCl, and
0.05% Tween 20) containing 3% serum bovine albumin, followed
by overnight incubation at 4 1C with the primary antibodies.
Blots were washed and incubated for 1 h at room temperature
with horseradish peroxidase-conjugated secondary antibodies.
Immunoreactive bands were visualized using the LAS-3000 imaging
system (Fujifilm, Tokyo, Japan).
Adhesion assay
Jurkat T-cell adhesion to ICAM-1-coated plates was performed as
described previously (Mor et al., 2009). Recombinant ICAM-1 was
produced as described previously (Mor et al., 2007b). Cells were
labeled with 5-carboxyuorescein. Cells (1.5 105) were plated for
20minutes before removal of non-adherent cells by serial washes.
The percentage of adherent cells was quantified with a plate reader
(Synergy HT, BioTek Instruments, Winooski, VT) reading emissions
at 525 nm.
Microscopy
Live cells were plated in 35-mm dishes containing a number 0 glass
coverslip over a 15-mm cutout (MatTek, Ashland, MA). Cells
were maintained at 37 1C using a PDMI-2 microincubator
(Harvard Apparatus, Holliston, MA). Individual cells were imaged
before and after addition of stimuli. Images were acquired with a
Zeiss 510 inverted laser scanning confocal microscope (Carl Zeiss
MicroImaging, Thornwood, NY) and processed with Adobe
Photoshop CS.
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Mice
The Institutional Ethics Committee of Tel Aviv University approved
the study.
BALB/c female mice at 8 to 10 weeks of age were used.
Oral administration of FTS-A required doses of 50 and 100mg kg1
(Barkan et al., 2006). DNFB and olive oil were obtained from Sigma-
Aldrich. Mice were sensitized on the shaved abdomen with 50 ml
of 0.5% DNFB in a vehicle of 4:l acetone:olive oil. Mice were
ear challenged with 20 ml of 0.2% DNFB in a vehicle of 4:l
acetone:olive oil after 5 days. A constant area of the ears was
measured immediately before challenge and at 24 hours later with
an engineer’s micrometer (Ozaki Mfg, Itabashi, Tokyo, Japan). Ear
swelling was expressed as the difference in ear thickness before and
after the challenge (Zimber et al., 1982). Betamethasone 0.05%
(W/W) was used as a positive control (NYU School of Medicine, NY).
Histology and immunohistochemistry
Mice ears were fixed in 4% paraformaldehyde, embedded in
paraffin, and cut in 4-mm-thick sections. Sections were stained with
hematoxylin and eosin, and with specific primary antibodies as
mentioned above. Bounding antibodies were detected with perox-
idase-based staining. As a negative control, sections were stained in
the absence of primary antibody as well as with isotype control sera.
Toluidine blue staining protocol was adopted from NYU core facility
(http://cores.med.nyu.edu).
Cytokines levels
Levels of serum TNF-a were determined at 48 hours after epicuta-
neous challenge using ELISA kit, according to the manufacturer’s
instructions (TNF-a HS ELISA kit, R&D Systems, Minneapolis, MN).
Statistical analysis
Significant differences between the control and variable conditions
in each experiment were determined by unpaired or paired Student’s
t-test, as appropriate using Microsoft Excel. A P-value of p0.05 was
considered significant. Data are given as mean±s.e.m.
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